X-ray snapshot of the mechanism of inactivation of human neutrophil elastase by 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives

Journal of Medicinal Chemistry

Volumn 51, Issue 7, 2008, Pages 2003-2008

  Huang, Weijun ^b   Yamamoto, Yasufumi ^b   Li, Yi ^a   Dou, Dengfeng ^a   Alliston, Kevin R ^a   Hanzlik, Robert P ^b   Williams, Todd D ^b   Groutas, William C ^a  

^a WICHITA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ELASTASE; SERINE; THIAZOLIDINE DERIVATIVE;

ARTICLE; BINDING SITE; COMPLEX FORMATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; ELECTROSPRAY MASS SPECTROMETRY; ENZYME BINDING; ENZYME INHIBITION; LEUKOCYTE ACTIVATION;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLIC S-OXIDES; ENZYME ACTIVATION; HUMANS; LEUKOCYTE ELASTASE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN STRUCTURE, TERTIARY; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 41849138945     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm700966p     Document Type: Article

References (44)

1. Silverman, R. B. Mechanism-Based Enzyme Inactivators. Methods Enzymol. 1995, 249, 240-283.
2. (a) Churg, A.; Wright, J. L. Proteases and Emphysema. Curr. Opin. Pulm. Med. 2005, 11, 153-159.
3. (b) Barnes, P. J. Mediators of Chronic Obstructive Pulmonary Disease. Pharmacol. Rev. 2004, 56, 515-548.
4. (c) Barnes, P. J.; Stockley, R. A. COPD: Current Therapeutic Interventions and Future Approaches. Eur. Respir. J. 2005, 25, 1984-1106.
5. (d) Shapiro, S. D.; Ingenito, E. P. The Pathogenesis of COPD. Am. J. Respir. Cell Mol. Biol. 2005, 32, 367-372.
6. (e) Shapiro, S. D.; Goldstein, N. M.; Houghton, A. M.; Kobayashi, D. K.; Kelley, D.; Belaaouaj, A. Neutrophil Elastase Contributes to Cigarette Smoke-Induced Emphysema in Mice. Am. J. Pathol. 2003, 163, 2329-2335.
7. (f) Rees, D. D.; Brain, J. D.; Wohl, M. E.; Humes, J. L.; Mumford, R. A. Inhibition of Neutrophil Elastase in CF Sputum by L-658,758. J. Pharmacol. Exp. Ther. 1997, 283, 1201-1206.
8. (g) Moraes, T. J.; Chow, C. W.; Downey, G. P. Proteases and Lung Injury. Crit. Care Med. 2003, 31, S189-S194.
9. (h) Balfour-Lynn, I. M. The Protease-Antiprotease Battle in the Cystic Fibrosis Lung. J. R. Soc. Med. 1999, 92, S23-S30.
10. (i) Van Der Geld, Y. M.; Limburg, P. C.; Kallenberg, C. G. Proteinase 3, Wegener's Autoantigen: From Gene to Antigen. J. Leuk. Biol. 2001, 69, 177-190.
11. (a) Groutas, W. C.; Kuang, R.; Venkataraman, R.; Epp, J. B.; Ruan, S.; Prakash, O. Structure-Based Design of a General Class of Mechanism-Based Inhibitors of the Serine Proteinases Employing a Novel Amino Acid-Derived Heterocyclic Scaffold. Biochemistry 1997, 36, 4739-4750.
12. (b) Groutas, W. C.; Kuang, R.; Ruan, S.; Epp, J. B.; Venkataraman, R.; Truong, T. M. Potent and Specific Inhibition of Human Leukocyte Elastase, Cathepsin G and Proteinase 3 by Sulfone Derivatives Employing the 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide Scaffold. Bioorg. Med. Chem. 1998, 6, 661-671.
13. (c) Kuang, R.; Venkataraman, R.; Ruan, S.; Groutas, W. C. Use of the 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide and Isothiazolidin-3-one 1,1-Dioxide Scaffolds in the Design of Potent Inhibitors of Serine Proteinases. Bioorg. Med. Chem. Lett. 1998, 8, 539-544.
14. (d) Kuang, R.; Epp, J. B.; Ruan, S.; Chong, L. S.; Venkataraman, R.; Tu, J.; He, S.; Truong, T. M.; Groutas, W. C. Utilization of the 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide Scaffold in the Design of Potent Inhibitors of Serine Proteases: SAR Studies Using Carboxylates. Bioorg. Med. Chem. 2000, 8, 1005-1016.
15. (e) He, S.; Kuang, R.; Venkataraman, R.; Tu, J.; Truong, T. M.; Chan, H-K.; Groutas, W. C. Potent Inhibition of Serine Proteases by Heterocyclic Sulfide Derivatives of 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide. Bioorg. Med. Chem. 2000, 8, 1713-1717.
16. (f) Wong, T.; Groutas, C. S.; Mohan, S.; Lai, Z.; Alliston, K. R.; Vu, N.; Schechter, N. M.; Groutas, W. C. 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide-Based Heterocyclic Sulfides are Potent Inhibitors of Human Tryptase. Arch. Biochem. Biophys. 2005, 436, 1-7.
17. (g) Wei, L.; Lai, Z.; Gan, X.; Alliston, K. R.; Zhong, J.; Epp, J. B.; Tu, J.; Perera, A. B.; Van Sipdonk, M.; Groutas, W. C. Mechanism-Based Inactivation of Human Leukocyte Elastase via an Enzyme-Induced Sulfonamide Fragmentation Process. Arch. Biochem. Biophys. 2004, 429, 60-70.
18. (h) Lai, Z.; Gan, X.; Wei, L.; Alliston, K. R.; Yu, H.; Li, Y. H.; Groutas, W. C. Potent Inhibition of Human Leukocyte Elastase by 1,2,5-Thiadiazolidin-one 1,1-Dioxide-Based Sulfonamide Derivatives. Arch. Biochem. Biophys. 2004, 429, 191-197.
19. 1′ is the scissile bond.
20. (a) Groutas, W. C.; Epp, J. B.; Kuang, R.; Ruan, S.; Chong, L. S.; Venkataraman, R.; Tu, J.; He, S.; Yu, H.; Fu, Q.; Li, Y-H.; Truong, T. M.; Vu, N. T. 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide: A Powerful Scaffold for Probing the S′ Subsites of (Chymo)trypsin-like Serine Proteases. Arch. Biochem. Biophys. 2001, 385, 162-169.
21. (b) Groutas, W. C.; He, S.; Kuang, R.; Ruan, S.; Tu, J.; Chan, H-K. Inhibition of Serine Proteases by Functionalized Sulfonamides Coupled to the 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide Scaffold. Bioorg. Med. Chem. 2001, 9, 1543-1548.
22. Kuang, R.; Epp, J. B.; Ruan, S.; Yu, H.; Huang, P.; He, S.; Tu, J.; Schechter, N. M.; Turbov, J.; Froelich, C. J.; Groutas, W. C. A General Inhibitor Scaffold for Serine Proteases with a (Chymo)trypsin-like Fold: Solution-Phase Construction of the First Series of Libraries of Mechanism-Based Inhibitors. J. Am. Chem. Soc. 1999, 121, 8128-8129.
23. (a) Abrahamson, D. R.; Irvin, M. H.; Blackburn, W. D.; Heck, L. W. Degradation of Basement Laminin by Human Neutrophil Elastase. Am. J. Pathol. 1990, 136, 1267-1274.
24. (b) Kafienah, W.; Buttle, D.; Hollander, A. P. Cleavage of Native Type I Collagen by Human Neutrophil Elastase. Biochem. J. 1998, 330, 897-902.
25. (c) Rao, N. V.; Wehner, N. G.; Marshall, B. C.; Gary, W. R.; Gray, B. H.; Hoidal, J. R. Characterization of Proteinase 3, A Neutrophil Serine Proteinase. Structural and Functional Properties. J. Biol. Chem. 1991, 266, 9540-9548.
26. Bode, W.; Meyer, E.; Powers, J. C. Human Leukocyte Elastase and Porcine Pancreatic Elastase: X-ray Crystal Structures, Mechanism, Substrate Specificity, and Mechanism-Based Inhibition. Biochemistry 1989, 28, 1951-1963.
27. Fujinaga, M.; Chenaia, M. M.; Halenbeck, R.; Koths, K.; James, M. N. G. The Crystal Structure of PR 3, A Neutrophil Serine Proteinase Antigen of Wegener's Granulomatosis Antibodies. J. Mol. Biol. 1996, 261, 267-278.
28. Brubaker, M. J.; Groutas, W. C.; Hoidal, J. R.; Rao, N. V. Human Neutrophil Proteinase 3: Mapping of the Substrate Binding Site Using Peptidyl Thiobenzyl Esters. Biochem. Biophys. Res. Comm. 1992, 188, 1318-1324.
29. Kam, C. M.; Kerrigan, J. E.; Dolman, K. M.; Goldschmeding, R.; Von dem Borne, A. E.; Powers, J. C. Substrate and Inhibitor Studies on Proteinase 3. FEBS Lett. 1992, 297, 119-123.
30. Korkmaz, B.; Knight, G.; Bieth, J. Compared Action of Neutrophil Proteinase 3 and Elastase on Model Substrates. Favorable Effect of S′-P′ Interactions on Proteinase 3 Catalysis. J. Biol. Chem. 2003, 278, 12609-12612.
31. Hajjar, E.; Korkmaz, B.; Gautheir, F.; Brandsdal, B. O.; Witko-Sarsat, V.; Reuter, N. Inspection of the Binding Sites of Proteinase 3 for the Design of a Highly Specific Substrate. J. Med. Chem. 2006, 49, 1248-1260.
32. (a) Morrison, J. F.; Walsh, C. T. The Behaviour and Significance of Slow Binding Inhibitors. Adv. Enzymol. 1988, 61, 201-301.
33. (b) Wakselman, M.; Xie, J.; Mazaleyrat, J. P. New Mechanism-Based Inhibitors of Trypsin-like Proteinases. Selective Inhibition of Urokinase by Functionalized Cyclopeptides Incorporating a Sulfonomethyl-Substituted m-Aminobenzoic Acid. J. Med. Chem. 1993, 36, 1539-1547.
34. (c) Weir, M. P.; Bethell, S. S.; Cleasby, A.; Campbell, C. J.; Dennis, R. J.; Dix, C. J.; Finch, H.; Jhoti, H.; Mooney, C. J.; Patel, S.; Tang, C-M.; Ward, M.; Wonacott, A. J.; Wharton, C. W. Novel Natural Product 5,5-trans-Lactone Inhibitors of Human alpha-Thrombin: Mechanism of Action and Structural Studies. Biochemistry 1998, 37, 6645-6657.
35. (d) Copeland, R. A. Evaluation of Enzyme Inhibitors. In Drug Discovery; Wiley: New York, 2005.
36. (a) Abbenante, G.; Fairlie, D. P. Protease Inhibitors in the Clinic. Med. Chem. 2005, 1, 71-104.
37. (b) Edwards, P. D. In Proteinase and Peptidase Inhibition; Smith, H. J., Simons, C., Eds.; Taylor and Francis: London, 2002.
38. (a) Nakayama, Y.; Odakagi, Y.; Fujita, S.; Matsuoka, S.; Kamanaka, N.; Nakai, H.; Toda, M. Clarification of the Mechanism of Human Sputum Elastase Inhibition by a New Inhibitor, ONO-5046, Using Electrospray Ionization Mass Spectrometry. Bioorg. Med. Chem. 2002, 12, 2349-2353.
39. (b) Knight, W. B.; Swiderek, K. M.; Sakuma, T.; Calaycay, J.; Shively, J. E.; Lee, T. D.; Covey, T. R.; Shushan, B.; Green, B. G.; Chabin, R.; Shah, S.; Mumford, R.; Dickinson, T. A.; Griffin, P. R. Electrospray Ionization Mass Spectrometry as a Mechanistic Tool: Mass of Human Leukocyte Elastase and a β-Lactam-Derived E-I Complex. Biochemistry 1993, 32, 2031-2035.
40. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276, 307-326.
41. Read, R. J. Pushing the Boundaries of Molecular Replacement with Maximum Likelihood. Acta Crystallogr. 2001, D57, 1373-1382.
42. Jones, T. A.; Zhou, J. Y.; Cowan, S. W.; Kjelgaard, M. Improved Methods for Building Protein Models in Electron Density Maps and the Location of Errors in These Models. Acta Crystallogr. 1991, 47, 110-119.
43. Brünger, A. T.; Adams, P. D.; Clore, G. M.; Delano, W. L.; Gros, P.; Grosse-Kunstleve, R. W. Crystallography and NMR System: A New Software Suite for Macromolecular Structure determination. Acta Crystallogr. 1998, 54, 905-921.
44. DeLano, W. L. The PyMOL Molecular Visualization System. http://www.pymol.org, 2002.